Skip to content

Intravenous Lidocaine, Ketamine, and Magnesium in Thoracic Surgery

Evaluation of Intraoperative Intravenous Lidocaine, Ketamine, and Magnesium on Postoperative Pain and Opioid Use After Pulmonary Resection: A Prospective Observational Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07359469
Acronym
LKM-Thorax
Enrollment
118
Registered
2026-01-22
Start date
2018-01-01
Completion date
2022-05-03
Last updated
2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multimodal Analgesia, Opioid Consumption, Postoperative, Postoperative Pain, Thoracic Surgery

Keywords

Multimodal analgesia, Lidocaine, Ketamine, Magnesium sulphate, Opioid consumption, VAS pain score, thoracotomy, VATS surgery

Brief summary

Thoracic surgery often produces severe postoperative pain due to nerve injury and inflammation. Effective pain control is essential to reduce complications and opioid use. This prospective observational cohort study evaluated adult patients undergoing pulmonary resection by thoracotomy or video-assisted thoracoscopic surgery (VATS). The study examined whether intraoperative administration of intravenous lidocaine, ketamine, and magnesium, used as part of multimodal analgesia, was associated with reduced postoperative morphine consumption and lower early postoperative pain scores. Outcomes included 24-hour morphine use, pain intensity at 3 and 24 hours, complications, and chronic pain at 3 months. No study-directed interventions were performed; anesthetic management followed routine clinical practice.

Detailed description

This prospective observational cohort study included 118 adult patients undergoing elective pulmonary resection between 2018 and 2022. The objective was to evaluate the association between intraoperative intravenous lidocaine, ketamine, and magnesium (LKM) and postoperative analgesic outcomes. Seventy-one patients received intraoperative LKM as part of a standardized multimodal analgesic protocol, consisting of lidocaine (1.5 mg/kg bolus followed by 1.5 mg/kg/h infusion), ketamine (0.3 mg/kg bolus), and magnesium sulfate (1.5 g bolus). Forty-seven patients received standard anesthesia without LKM administration. No study-specific interventions were assigned; exposure was based on routine anesthetic practice. The primary outcome was total intravenous morphine consumption during the first 24 postoperative hours. Secondary outcomes included pain scores (VAS) at 3 and 24 hours, incidence of chronic postoperative pain at 3 months, pulmonary and cardiovascular complications, renal injury, thromboembolic events, hospital length of stay, and mortality. Safety monitoring included hypotension, bradycardia, arrhythmias, hallucinations, and delayed emergence from anesthesia. This study aimed to identify perioperative factors influencing postoperative pain and opioid use after thoracic surgery, while evaluating the potential benefit of LKM within a multimodal analgesia strategy. All patients provided informed consent, and the study was approved by the local ethics committee. Data collection and clinical management followed standard institutional protocols.

Interventions

None listed

Sponsors

Universidad Pública de Navarra
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged 18 years or older. * Scheduled for elective pulmonary resection (thoracotomy or VATS). * Able to provide informed consent. * ASA physical status I-IV.

Exclusion criteria

* Emergency surgery. * Known allergy or contraindication to lidocaine, ketamine, or magnesium. * Severe hepatic insufficiency. * Severe renal dysfunction (eGFR \< 30 mL/min/1.73 m²). * Pre-existing significant arrhythmias (e.g., uncontrolled atrial fibrillation, ventricular arrhythmias). * Pregnancy. * Cognitive impairment preventing valid informed consent. * Patients receiving chronic intravenous analgesics or regional anesthesia techniques preoperatively.

Design outcomes

Primary

MeasureTime frameDescription
Total intravenous morphine consumption within the first 24 hours postoperatively.First 24 postoperative hoursTotal amount of intravenous morphine administered during the first 24 postoperative hours. Values will be recorded in milligrams (mg). Higher values indicate greater opioid consumption.

Secondary

MeasureTime frameDescription
Pain intensity at 3 and 24 hours postoperatively, assessed using a 10-point Visual Analogue Scale (VAS), chronic pain ( 3 months)3 hours, 24 hours, and 3 months after surgeryPain intensity assessed using a 10-point Visual Analogue Scale (VAS), where 0 represents no pain and 10 represents the worst imaginable pain. Measurements will be recorded at 3 hours, 24 hours, and 3 months after surgery. Higher scores indicate greater pain intensity. Pain persisting at 3 months will be classified as chronic post-surgical pain.

Countries

Spain

Contacts

PRINCIPAL_INVESTIGATORManuel Murie Fernandez, MD, PhD

Universidad Pública de Navarra ( UPNA)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026